NovoCure secures Japan approval as target for NovoCure stock reaches USD 21.20
Published on 10/20/2026 at 13:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOptune Pax and earnings calendar
- Japan approval followed a Phase 3 trial in which 76.3 percent of treated participants experienced skin-related adverse events on October 1, 2026.
- Second-quarter revenue reached USD 183.58 million, up 15.60 percent year over year.
- NovoCure stock trades at EUR 13.44 at 1:19 p.m. CEST at Lang & Schwarz on October 20, 2026.
- MarketBeat reported an average 12-month price target of USD 21.20 on October 17, 2026.
NovoCure (ISIN JE00BYSS4X48) secured Japanese approval for Optune Pax on October 1, 2026, while MarketBeat reported an average 12-month price target of USD 21.20 on October 17, 2026. The regulatory decision gives the oncology company another commercial market before its third-quarter results.
Japan adds a commercial market
According to Business Wire, Japan's Ministry of Health, Labour and Welfare approved Optune Pax for adults with unresectable locally advanced pancreatic cancer, to be used with gemcitabine and nab-paclitaxel. The approval followed the Phase 3 PANOVA-3 trial, which showed a statistically significant improvement in median overall survival versus chemotherapy alone.
The safety profile remains a commercial consideration. Skin-related adverse events occurred in 76.3 percent of Optune Pax-treated participants in PANOVA-3, while 7.7 percent experienced a Grade 3 or higher event, according to the company release carried by Business Wire.
What does Q2 mean for earnings?
NovoCure reported second-quarter 2026 revenue of USD 183.58 million, up 15.60 percent from the prior-year quarter, while adjusted loss per share was USD 0.13 against a USD 0.33 consensus loss, MarketBeat reported on October 17, 2026. The result combined faster sales growth with continuing losses, leaving the October report as the next test of operating leverage.
Three events set the timeline
On July 23, 2026, NovoCure reported second-quarter revenue of USD 183.58 million. On October 1, 2026, the company announced that it would report third-quarter results on October 29, 2026, at 8:00 a.m. EDT. Also on October 1, 2026, Japan approved Optune Pax after the PANOVA-3 trial showed a survival benefit, making the regulatory decision the latest event in this sequence.
October 29 results set the next test
The next substantiated date is October 29, 2026, for third-quarter results before the U.S. market opens, followed by an 8:00 a.m. EDT conference call, according to Novocure. MarketBeat listed a consensus revenue estimate of USD 182.28 million and a consensus loss of USD 0.2349 per share for that quarter.
NovoCure's primary listing is Nasdaq, where the stock closed at USD 14.89 on October 19, 2026, at 4:00 p.m. EDT. Market capitalization was USD 1.7 billion as of October 20, 2026, while the reported 52-week range was USD 9.82 to USD 21.45.
NovoCure stock was trading at EUR 13.44 at Lang & Schwarz on October 20, 2026 at 1:19 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of NovoCure stock.
NovoCure stock facts
- Company: NovoCure Limited
- ISIN: JE00BYSS4X48
- Ticker: NVCR
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 1:19 p.m. CEST): EUR 13.44
- Sector / Industry: Health Care / Medical Equipment, Supplies and Distribution
- Market capitalization: USD 1.7 billion (as of October 20, 2026)
- 52-week range: USD 9.82-21.45 (as of October 20, 2026)
- Next earnings date: October 29, 2026
Market context: Market report Nasdaq Composite.
